Bavarian Nordic A/S (BVNRY)
USD 8.07
(3.2%)
USD 8.07
(3.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.06 Billion DKK | 123.99% |
| 2022 | 3.15 Billion DKK | 66.02% |
| 2021 | 1.89 Billion DKK | 2.46% |
| 2020 | 1.85 Billion DKK | 179.61% |
| 2019 | 662.48 Million DKK | 32.33% |
| 2018 | 500.61 Million DKK | -63.46% |
| 2017 | 1.37 Billion DKK | 36.1% |
| 2016 | 1 Billion DKK | -1.35% |
| 2015 | 1.02 Billion DKK | -16.13% |
| 2014 | 1.21 Billion DKK | 0.36% |
| 2013 | 1.21 Billion DKK | 19.27% |
| 2012 | 1.01 Billion DKK | 94.16% |
| 2011 | 523.6 Million DKK | 66.71% |
| 2010 | 314.07 Million DKK | 319.98% |
| 2009 | 74.78 Million DKK | -64.19% |
| 2008 | 208.8 Million DKK | -37.13% |
| 2007 | 332.1 Million DKK | 89.46% |
| 2006 | 175.29 Million DKK | -29.2% |
| 2005 | 247.59 Million DKK | 50.26% |
| 2004 | 164.78 Million DKK | -67.35% |
| 2003 | 504.64 Million DKK | 316.79% |
| 2002 | 121.07 Million DKK | 0.0% |
| 2001 | - DKK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.42 Billion DKK | 71.68% |
| 2024 Q1 | 831.47 Million DKK | -66.05% |
| 2023 FY | 7.05 Billion DKK | 123.99% |
| 2023 Q4 | 2.44 Billion DKK | 77.96% |
| 2023 Q1 | 1.25 Billion DKK | -2.98% |
| 2023 Q3 | 1.37 Billion DKK | -30.72% |
| 2023 Q2 | 1.98 Billion DKK | 58.67% |
| 2022 Q3 | 1 Billion DKK | 86.99% |
| 2022 Q4 | 1.29 Billion DKK | 28.59% |
| 2022 Q1 | 320.05 Million DKK | -41.16% |
| 2022 Q2 | 536.69 Million DKK | 67.69% |
| 2022 FY | 3.15 Billion DKK | 66.02% |
| 2021 Q1 | 535.25 Million DKK | 133.82% |
| 2021 Q3 | 448.65 Million DKK | 21.26% |
| 2021 FY | 1.89 Billion DKK | 2.46% |
| 2021 Q4 | 543.96 Million DKK | 21.24% |
| 2021 Q2 | 369.99 Million DKK | -30.87% |
| 2020 Q2 | 699.57 Million DKK | 91.45% |
| 2020 Q1 | 365.4 Million DKK | 25.92% |
| 2020 Q4 | 228.91 Million DKK | -59.01% |
| 2020 FY | 1.85 Billion DKK | 179.61% |
| 2020 Q3 | 558.48 Million DKK | -20.17% |
| 2019 Q4 | 290.19 Million DKK | 101.38% |
| 2019 Q1 | 126.83 Million DKK | -30.02% |
| 2019 Q2 | 101.36 Million DKK | -20.08% |
| 2019 FY | 662.48 Million DKK | 32.33% |
| 2019 Q3 | 144.09 Million DKK | 42.16% |
| 2018 Q2 | 86.34 Million DKK | 664.48% |
| 2018 Q4 | 181.25 Million DKK | -18.26% |
| 2018 Q1 | 11.29 Million DKK | -72.39% |
| 2018 FY | 500.61 Million DKK | -63.46% |
| 2018 Q3 | 221.73 Million DKK | 156.81% |
| 2017 Q3 | 734.27 Million DKK | 84.83% |
| 2017 Q4 | 40.9 Million DKK | -94.43% |
| 2017 FY | 1.37 Billion DKK | 36.1% |
| 2017 Q1 | 197.69 Million DKK | -52.4% |
| 2017 Q2 | 397.27 Million DKK | 100.95% |
| 2016 Q1 | 22.55 Million DKK | -92.9% |
| 2016 Q2 | 116.55 Million DKK | 416.7% |
| 2016 FY | 1 Billion DKK | -1.35% |
| 2016 Q3 | 452.29 Million DKK | 288.05% |
| 2016 Q4 | 415.33 Million DKK | -8.17% |
| 2015 FY | 1.02 Billion DKK | -16.13% |
| 2015 Q4 | 317.54 Million DKK | 301.45% |
| 2015 Q3 | 79.1 Million DKK | -79.67% |
| 2015 Q2 | 389.1 Million DKK | 65.72% |
| 2015 Q1 | 234.8 Million DKK | -56.62% |
| 2014 Q3 | 225.2 Million DKK | 36.9% |
| 2014 Q4 | 541.21 Million DKK | 140.33% |
| 2014 FY | 1.21 Billion DKK | 0.36% |
| 2014 Q1 | 285.9 Million DKK | -15.29% |
| 2014 Q2 | 164.5 Million DKK | -42.46% |
| 2013 Q2 | 350.4 Million DKK | 70.35% |
| 2013 Q3 | 318.9 Million DKK | -8.99% |
| 2013 Q4 | 337.5 Million DKK | 5.83% |
| 2013 FY | 1.21 Billion DKK | 19.27% |
| 2013 Q1 | 205.7 Million DKK | -22.91% |
| 2012 Q3 | 304.4 Million DKK | 9.65% |
| 2012 Q2 | 277.6 Million DKK | 65.44% |
| 2012 Q4 | 266.83 Million DKK | -12.34% |
| 2012 FY | 1.01 Billion DKK | 94.16% |
| 2012 Q1 | 167.8 Million DKK | -54.49% |
| 2011 Q4 | 368.7 Million DKK | 279.71% |
| 2011 Q3 | 97.1 Million DKK | 232.53% |
| 2011 FY | 523.6 Million DKK | 66.71% |
| 2011 Q2 | 29.2 Million DKK | 2.1% |
| 2011 Q1 | 28.6 Million DKK | -69.85% |
| 2010 Q3 | 43.7 Million DKK | -73.01% |
| 2010 FY | 314.07 Million DKK | 319.98% |
| 2010 Q4 | 94.87 Million DKK | 117.1% |
| 2010 Q2 | 161.9 Million DKK | 1099.26% |
| 2010 Q1 | 13.5 Million DKK | -37.45% |
| 2009 Q3 | 20.3 Million DKK | 28.48% |
| 2009 Q4 | 21.58 Million DKK | 6.32% |
| 2009 FY | 74.78 Million DKK | -64.19% |
| 2009 Q2 | 15.8 Million DKK | -7.6% |
| 2009 Q1 | 17.1 Million DKK | 0.0% |
| 2008 FY | 208.8 Million DKK | -37.13% |
| 2007 FY | 332.1 Million DKK | 89.46% |
| 2006 FY | 175.29 Million DKK | -29.2% |
| 2005 FY | 247.59 Million DKK | 50.26% |
| 2004 FY | 164.78 Million DKK | -67.35% |
| 2003 FY | 504.64 Million DKK | 316.79% |
| 2002 FY | 121.07 Million DKK | 0.0% |
| 2001 FY | - DKK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -1160466.945% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1721729.02% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -38665.726% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -9326322.27% |
| Biomind Labs Inc. | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 51.924% |
| CytoDyn Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -365445.549% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -2985332.871% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -5643.896% |
| SQZ Biotechnologies Company | 21.47 Million USD | -32781.739% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -7134009.138% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -44674.868% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -10744696.738% |
| Mesoblast Limited | 5.9 Million USD | -119560.115% |
| Marizyme, Inc. | 645.81 Thousand USD | -1093463.122% |
| Genus plc | 668.8 Million USD | -955.972% |
| Pharming Group N.V. | 245.31 Million USD | -2778.875% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -9200327.3% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -17871097.935% |
| MultiCell Technologies, Inc. | 49.32 USD | -14319424068.694% |
| ONE Bio Corp. | 52.29 Million USD | -13404.499% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -14103.938% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -23761.675% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -1266210.448% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -10088957.143% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -1072388.99% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| Enzolytics Inc. | 52.79 Thousand USD | -13376557.323% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | -475.899% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -5035723.79% |
| Genscript Biotech Corporation | 839.52 Million USD | -741.226% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -40079010.153% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -707743.636% |
| EV Biologics, Inc. | 48.9 Thousand USD | -14442313.088% |
| Q BioMed Inc. | 284.35 Thousand USD | -2483561.096% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -14505.493% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -4767.235% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -42226.452% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -706940840.941% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1143813.674% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -2985332.871% |
| Affymax, Inc. | 1.36 Million USD | -515775.822% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -90570.689% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -1490694.334% |
| SYBLEU INC | 11.69 Thousand USD | -60382423.94% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -54325592.308% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -17863865.195% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -211982.282% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -105861.59% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -679624.735% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -27308.468% |
| CSL Limited | 14.8 Billion USD | 52.281% |
| Cellectis S.A. | 755 Thousand USD | -935309.272% |